The FDA has approved teclistamab-cqyv in combination with daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma who received at least one prior line of therapy.
As the third approval under the Commissioner’s National Priority Voucher pilot program, teclistamab-cqyv (Tecvayli, Johnson & Johnson) plus daratumumab hyaluronidase-fihj (Darzalex Faspro, Johnson & Johnson) is now cleared for patients with relapsed or refractory multiple myeloma who previously received either a proteasome inhibitor or an immunomodulatory agent.
This approval also upgrades